Table 1.

Characteristics of the included studies.

S.No	Author	Year	Study Design	Population Study	Outcome
1.	Northup PG	2010	Multivariable Analysis	934	The study found no variance in the total number of patients that survived between those who were given HCV-positive donor livers and those who were given the HCV-negative. The relation index between the two clusters was clinically inconsequential at 1.82 for HCV-positive donors versus 1.78 for HCV-negative donors.
2.	Ballarin et al.	2011	Case-Control Study	63	This study also showed no variation in the number of patients who survived at 1 and 5 years (p = 0.22 and 0.11, respectively). Allograft pathology revealed that HCV-positive donor livers had higher histological activity index numbers (17.5% vs. 3.2% for scores 5–8, p = 0.01) and stage I fibrosis (52.4% vs. 17.5%, p < 0.001).
3.	Berenguer M et al.	2008	Systematic Review	19 studies, 611 patients	The mean SVR in this patient cohort was only 30.2%, partly due to unfavorable events that required doses to be reduced or the treatment to be terminated.
4.	Charlton et al.	2015	Prospective Open-Label Study	40 patients	Interventions with sofosbuvir and ribavirin occasioned a sustained virological response at 12 weeks (SVR12) in 70% of the patients.
5.	Pungpapong S et al.	2015	Multicenter Study	123 HCV-positive liver transplant patients	In the subjects that received interventions with simeprevir and sofosbuvir with or without ribavirin, 90% achieved SVR, with the bulk of patients suffering only slight adverse repercussions.
6.	Forns et al.	2015	Case Study	104 patients	This study established that treatment with sofosbuvir and ribavirin, with or without pegylated intervention, resulted in SVR 12 in 59% of the patients.
7.	Leroy et al.	2015	Case Study	23 patients	22 of 23 patients (96% of the population) with fibrosing cholestatic hepatitis achieved SVR12 following treatment with sofosbuvir and ribavirin with or without pegylated-interferon or sofosbuvir and daclatasvir with or without ribavirin.
8.	Kapila N et al.	2020	Case Study	45 patients	Cleveland Clinic Florida reported their findings on kidney transplantation of HCV-positive organs, with only one of the treatments failing: 41 patients achieving SVR12.
9.	Durand CM et al.	2018	Case Study	Ten patients	Their EXPANDER study registered ten kidney transplant recipients, but it did not restrict them to genotype 1. Determining the HCV genotype was done at the time of transplantation, and reported in a week. All the recipients were given 12 weeks of elbasvir-grazoprevir. The initial dose was given on call to the operating room and midway through from the initial amount to reperfusion of the new kidney at 5.1 h. For 3 out of the 10 patients who had genotype 2 or 3, sofosbuvir was included in the regimen. All the patients attained SVR12.
10.	Schlendorf KH et al.	2018	Case Study	37 patients, heart transplant	In this study, all 37 patients who took the treatment to completion achieved SVR12.